These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 2451273)
1. Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c. Garred P; Mollnes TE; Lea T; Fischer E Scand J Immunol; 1988 Mar; 27(3):319-27. PubMed ID: 2451273 [TBL] [Abstract][Full Text] [Related]
2. Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c. Laursen SB; Thiel S; Teisner B; Holmskov U; Wang Y; Sim RB; Jensenius JC Immunology; 1994 Apr; 81(4):648-54. PubMed ID: 7518801 [TBL] [Abstract][Full Text] [Related]
3. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Garred P; Mollnes TE; Lea T Scand J Immunol; 1988 Mar; 27(3):329-35. PubMed ID: 2451274 [TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b. Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466 [TBL] [Abstract][Full Text] [Related]
5. Enzyme immunoassay detection of circulating immune complexes by monoclonal antibodies to C3 neoepitopes with special reference to IgG concentration and to interfering anti-immunoglobulin antibodies. Garred P; Mollnes TE; Lea T; Lachmann PJ J Immunol Methods; 1989 Feb; 117(1):59-66. PubMed ID: 2464039 [TBL] [Abstract][Full Text] [Related]
6. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin. Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880 [TBL] [Abstract][Full Text] [Related]
7. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g. Davis AE; Harrison RA; Lachmann PJ J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952 [TBL] [Abstract][Full Text] [Related]
8. The attachment of serum- and plasma-derived C3 to solid-phase immune aggregates and its relation to complement-mediated solubilization of immune complexes. Baatrup G; Svehag SE; Jensenius JC Scand J Immunol; 1986 Apr; 23(4):397-406. PubMed ID: 3486458 [TBL] [Abstract][Full Text] [Related]
9. Detection of a neoantigen on human C3bi and C3d by monoclonal antibody. Tamerius JD; Pangburn MK; Müller-Eberhard HJ J Immunol; 1985 Sep; 135(3):2015-9. PubMed ID: 2410510 [TBL] [Abstract][Full Text] [Related]
10. A solid-phase anti-C3 assay for detection of immune complexes in six distinguished forms. Iida K; Mitomo K; Fujita T; Tamura N J Immunol Methods; 1987 Apr; 98(1):23-8. PubMed ID: 2435809 [TBL] [Abstract][Full Text] [Related]
11. Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Mollnes TE; Redl H; Høgåsen K; Bengtsson A; Garred P; Speilberg L; Lea T; Oppermann M; Götze O; Schlag G Clin Exp Immunol; 1993 Feb; 91(2):295-300. PubMed ID: 7679061 [TBL] [Abstract][Full Text] [Related]
12. Synthesis of soluble C3 and C9 neoepitopes by human alveolar macrophages in vitro. Pettersen HB; Johnson E; Mollnes TE; Garred P Scand J Immunol; 1988 Oct; 28(4):431-4. PubMed ID: 2461585 [TBL] [Abstract][Full Text] [Related]
13. Effect of antigen site and complement receptor status on the rate of cleavage of C3c antigen from red cell bound C3b. Currie MS; Rustagi PK; Wojcieszak R; Ziolkowski L; Ross GD; Logue GL Blood; 1988 Mar; 71(3):786-90. PubMed ID: 3345346 [TBL] [Abstract][Full Text] [Related]
14. The apolipoprotein(a) moiety of lipoprotein(a) interacts with the complement activation fragment iC3b but does not functionally affect C3 activation or degradation. Seifert PS; Roth I; Zioncheck TF Atherosclerosis; 1992 Apr; 93(3):209-16. PubMed ID: 1534227 [TBL] [Abstract][Full Text] [Related]
15. Production of mouse monoclonal antibodies that detect distinct neoantigenic epitopes on bound C3b and iC3b but not on the corresponding soluble fragments. Nilsson B; Svensson KE; Borwell P; Nilsson UR Mol Immunol; 1987 May; 24(5):487-94. PubMed ID: 2443836 [TBL] [Abstract][Full Text] [Related]
16. Direct quantitation of activated C3 in human plasma with monoclonal anti-iC3b-C3d-neoantigen. Kanayama Y; Kurata Y; McMillan R; Tamerius JD; Negoro N; Curd JG J Immunol Methods; 1986 Apr; 88(1):33-6. PubMed ID: 2420896 [TBL] [Abstract][Full Text] [Related]
17. Generation of a C3c specific monoclonal antibody and assessment of C3c as a putative inflammatory marker derived from complement factor C3. Palarasah Y; Skjodt K; Brandt J; Teisner B; Koch C; Vitved L; Skjoedt MO J Immunol Methods; 2010 Oct; 362(1-2):142-50. PubMed ID: 20869965 [TBL] [Abstract][Full Text] [Related]
18. Autoantibodies Against C3b-Functional Consequences and Disease Relevance. Vasilev VV; Radanova M; Lazarov VJ; Dragon-Durey MA; Fremeaux-Bacchi V; Roumenina LT Front Immunol; 2019; 10():64. PubMed ID: 30761135 [TBL] [Abstract][Full Text] [Related]
19. Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. Lachmann PJ; Pangburn MK; Oldroyd RG J Exp Med; 1982 Jul; 156(1):205-16. PubMed ID: 6177820 [TBL] [Abstract][Full Text] [Related]